Dtsch Med Wochenschr 2019; 144(01): 28-33
DOI: 10.1055/a-0659-0999
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

COPD: Die wichtigsten Komorbiditäten

Comorbidities in Chronic Obstructive Pulmonary Disease
Carmen Pizarro
,
Dirk Skowasch
Further Information

Publication History

Publication Date:
02 January 2019 (online)

Abstract

Patients with chronic obstructive pulmonary disease (COPD) are frequently afflicted by comorbidities. In terms of quality of life, health status and prognosis, comorbid conditions negatively impact the lives of the sufferers. The link between these diseases is complex and comprises manifold considerations: it may be mediated by common risk factors, notably smoking, or by sequelae of COPD, like physical inactivity. Moreover, systemic inflammatory processes and mechanistic considerations seem to play a central role. As symptomatology is frequently overlapping, comorbid diseases tend to be overlooked. In consequence, they require proactive diagnostic approaches. Treatment should adhere to current guidelines, irrespective of the presence of COPD.

Die chronisch obstruktive Lungenerkrankung (COPD) wird häufig von Komorbiditäten begleitet, die nachhaltig die Lebensqualität und die Prognose der Patienten beeinflussen können. Dieser Beitrag widmet sich koexistenten Krankheitsbildern, die aufgrund der überlappenden Symptomatologie oft unter dem Deckmantel der COPD fehlinterpretiert werden. Sie sollten proaktiv diagnostiziert und einer leitlinienkonformen Therapie zugeführt werden.

 
  • Literatur

  • 1 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD (2018 Report). Im Internet: http://goldcopd.org/gold-reports/ ; Stand: 02.08.2018
  • 2 Vogelmeier C, Buhl R, Burghuber O. et al. Guideline for the Diagnosis and Treatment of COPD Patients. Pneumologie 2018; 72: 253-308
  • 3 Divo M, Cote C, de Torres JP. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161
  • 4 Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115-122
  • 5 Karch A, Vogelmeier C, Welte T. et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med 2016; 114: 27-37
  • 6 Ukena C, Mahfoud F, Kindermann M. et al. The cardiopulmonary continuum systemic inflammation as “common soil” of heart and lung disease. Int J Cardiol 2010; 145: 172-176
  • 7 Pizarro C, Herweg-Steffens N, Buchenroth M. et al. Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis 2016; 11: 2081-2089
  • 8 Rothnie KJ, Smeeth L, Herrett E. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart 2015; 101: 1103-1110
  • 9 Bhatt SP, Wells JM, Kinney GL. et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71: 8-14
  • 10 Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Im Internet: http://www.clinicaltrials.gov/ct2/show/NCT02587351 ; Stand: 02.08.2018
  • 11 Criner GJ, Connett JE, Aaron SD. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-2210
  • 12 Vestbo J, Anderson JA, Brook RD. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817-1826
  • 13 Hohlfeld JM, Vogel-Claussen J, Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 2018; 6: 368-378
  • 14 Alter P, Jörres RA, Watz H. et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol 2018; 261: 172-178
  • 15 Skowasch D, Pizarro C. COPD – You’ll never walk alone. Int J Cardiol 2018; 261: 181-182
  • 16 Mannino DM, Thorn D, Swensen A. et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969
  • 17 Scanlon PD, Connett JE, Wise RA. et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302-1309
  • 18 Maltais F, Decramer M, Casaburi R. et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: e15-e62
  • 19 Panagioti M, Scott C, Blakemore A. et al. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 1289-1306
  • 20 Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis 2014; 9: 315-330